If you made any changes in Pure these will be visible here soon.

Personal profile

Personal information

Dr. Ellen Langemeijer studied Molecular and Cellular Biology at Vrije  Universiteit Amsterdam, where she graduated in 1998. Upon graduation, she worked for six years at Galapagos Genomics as a scientist on diverse research projects, including the development of the patented adenoviral SilenceSelect knock-down library. 

Langemeijer returned to the VU in 2005 and started her PhD research at the Medicinal Chemistry research group. Supervised by Prof. Martine Smit, she worked on oncomodulatory signaling, by two herpesvirus-encoded G protein-coupled receptors (GPCRs), US28 and UL33. Subsequently, she was a post-doctoral researcher in the group of Prof. Ad IJzerman at Leiden University, studying functional selectivity of ligands for the adenosine receptors, also GPCRs.

Early 2013, Langemeijer returned to the Department of Chemistry and Pharmaceutical Sciences at VU University, joining the managing entity of SafeSciMET; an European Modular Education and Training Programme in Safety Sciences for Medicines, coordinated by Prof. Nico Vermeulen. In July 2013, Langemeijer became managing director of the Amsterdam Institute for Molecules, Medicines and Systems (AIMMS). As of 2018, she is project manager for the MSCA-funded in3-ITN, short for Integrating In vitro and In silico tools for toxicological screening, in the group of Prof. Paul Jennings at Vrije Universiteit Amsterdam.

Ancillary activities

No ancillary activities

Ancillary activities are updated daily


Dive into the research topics where E Langemeijer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or